Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man

Andrew J Boyle1*, Yerem Yeghiazarians1, Henry Shih1, Joy Hwang1, Jianqin Ye1, Rich Sievers1, Daiwei Zheng1, Jath Palasubramaniam2, Dharshan Palasubramaniam2, Connie Karschimkus2, Robert Whitbourn2, Alicia Jenkins2 and Andrew M Wilson2

Abstract

Background: Stem cell homing to the heart is mediated by the release of chemo-attractant cytokines. Stromal derived factor -1 alpha (SDF-1a) and monocyte chemotactic factor 1 (MCP-1) are detectable in peripheral blood after myocardial infarction (MI). It remains unknown if they are produced by, and released from, the heart in order to attract stem cells to repair the damaged myocardium.

Methods: Murine hearts were studied for expression of MCP-1 and SDF-1a at day 3 and day 28 following myocardial infarction to determine whether production is increased following MI. In addition, we studied the coronary artery and coronary sinus (venous) blood from patients with normal coronary arteries, stable coronary artery disease (CAD), unstable angina and MI to determine whether these cytokines are released from the heart into the systemic circulation following MI.

Results: Both MCP-1 and SDF-1a are constitutively produced and released by the heart. MCP-1 mRNA is upregulated following murine experimental MI, but SDF-1a is suppressed. There is less release of SDF-1a into the systemic circulation in patients with all stages of CAD including MI, mimicking the animal model. However MCP-1 release from the human heart following MI is also suppressed, which is the exact opposite of the animal model.

Conclusions: SDF-1a and MCP-1 release from the human heart are suppressed following MI. In the case of SDF-1a, the animal model appropriately reflects the human situation. However, for MCP-1 the animal model is the exact opposite of the human condition. Human observational studies like this one are paramount in guiding translation from experimental studies to clinical trials.

Background

The adult mammalian heart has limited capacity for self-repair. Enhancing the heart’s own reparative mechanisms represents an attractive therapeutic option for patients who have suffered myocardial infarction (MI). Stem cell chemo-attractant cytokines are thought to be released from the heart in response to injury, in an attempt to stimulate endogenous tissue repair pathways. Monocyte chemotactic protein-1 (MCP-1, CCL2) and stromal-derived factor 1 alpha (SDF-1a, CXCL12) are two stem cell chemo-attractant cytokines that are thought to play a role in post-infarct cardiac repair.

SDF-1a is constitutively expressed by many tissues, including the heart [1]. Following MI, cardiac SDF-1a is thought to contribute to a stem cell cytokine gradient that causes homing of stem cells to the heart [2,3]. For this to occur, SDF-1a must be produced in the heart and released into the circulation. Experimental models have yielded conflicting data about cardiac expression of SDF-1a, with some finding increased expression after MI [2,4-6] and others finding decreased expression [1,7]. Furthermore, the data concerning serum levels of circulating SDF-1a are also conflicting. In patients, some studies find increased levels after MI [8,9], while others...
find no change [10]. In rodent experimental MI, the serum level of SDF-1a is actually reduced [2], whereas in the canine model it is increased [1]. Thus, whether SDF-1a is released from the heart to create a cytokine gradient following MI remains unknown.

The role of MCP-1 in post-infarction left ventricular (LV) remodeling is complex. MCP-1 has been implicated in numerous steps along the way to post-infarction heart failure: in the development of atherosclerosis [11], in atherosclerotic plaque instability [12], in recruitment of monocytes to the heart following MI [13] and in post-infarction LV remodeling [14]. In experimental animal models, MCP-1 is also chemoattractant for stem cells [15,16]. MCP-1 levels are increased in peripheral blood following MI, both in rats [17] and in patients [18-20] and these levels correlate with prognosis [21]. It has been assumed that these peripheral blood levels are reflective of cardiac release causing a chemo-attractant cytokine gradient towards the heart. Thus modulation of the MCP-1/CCR2 axis has been proposed as a novel therapeutic target to treat post-infarction LV remodeling [14,21].

It is not clear whether the serum levels of these cytokines after MI is reflective of cardiac production and release, or whether they are coming from other tissues. Before clinical trials utilizing these cytokines as potential therapeutic agents are undertaken, these questions must be addressed. We therefore have studied the murine and human patterns of myocardial production and release of these cytokines in response to MI.

**Methods**

**Animal study**

Male C57BL/6J were used for all murine experiments. Animals were handled according to the guidelines of the Institutional Animal Care and Use Committee at the University of California San Francisco.

**Myocardial infarction**

MIs were induced surgically by a permanent ligation of the left anterior descending (LAD) coronary artery as previously described [22]. Briefly, after intubation and ventilation, thoracotomy is performed and permanent ligation of the LAD is made by a 7-0 suture in the anterior myocardium at 50% of the length of the heart from the anterior-inferior edge of the left atrium to the apex.

**Tissue preparation and analysis**

Animals were humanely sacrificed under general anesthesia. Baseline non-infarcted animals (n = 3) were compared with post-infarct animals at 2 time-points following MI: early (day 3; n = 3) and late (day 28; n = 3). Hearts were arrested in diastole with injection of concentrated KCl and the hearts immediately removed. For RNA analysis, the left ventricle was dissected away from the rest of the heart, divided into infarct, border and remote zones, and rapidly frozen by immersion in liquid nitrogen. Total RNA was isolated from left ventricles by TRizol reagent (Invitrogen). Trace genomic DNA in total RNA was removed by Dnase I and Rnase Mini Kit (Qiagen). cDNA was generated from 0.1 mg of total RNA by using SuperScript III First-Strand Synthesis kit (Invitrogen). Microarrays were performed using Affymetrix 1.0 Mouse gene chip. Data were normalized using robust multi-array average (RMA) method. Control and low performing probesets (those with intensity values below a threshold across all samples, the threshold was taken to be the global lowest 25th percentile of intensity values) were excluded from analysis. Also, based on Affymetrix’s annotation information, only those probesets which were part of the main design of the array and perfectly matching only one sequence were considered for analysis of differential expression. 20648 out of 35557 probesets remained after filtering.

**Human Study**

The human clinical study was approved by the Human Research Ethics Committee at St Vincent’s Hospital Melbourne Australia. Patients undergoing cardiac catheterization or cardiac surgery gave written informed consent for blood samples to be taken from the coronary artery/ aortic root and coronary sinus. For the cardiac catheterization patients, blood was taken from the coronary artery ostium via the cardiac catheter used for the case. A catheter was placed into the coronary sinus under fluoroscopic guidance and a sample was taken from the sinus at the same time. For the cardiac surgery patients, during cannulation of the heart in preparation for bypass, blood samples were taken from the coronary sinus (retrograde cardioplegia catheter) and from the aortic root (aortic bypass cannula). Importantly, in order to eliminate white blood cell activation from the bypass pump confounding our results, samples were taken before initiation of cardiopulmonary bypass and the blood had not entered the pump circuit. The blood was separated into serum and plasma and stored at -80 degrees C. For cytokine levels, ELISA was performed using antibodies to MCP-1 and SDF-1a R and D systems, (Minneapolis MN) according to the manufacturer’s protocol. The degree of coronary artery disease was assessed by an experienced cardiologist who was blinded to the results of the serum analysis. Patients were placed into categories depending on the degree of coronary artery disease, the clinical presentation and the results of serum cardiac enzymes and electrocardiogram (ECG). Patients were then described as angiographically normal coronary arteries, stable coronary artery disease, unstable angina and acute MI.

**Statistical analysis**

For murine mRNA studies, moderated t-statistics (as implemented in the limma package in R/Bioconductor)
were used to test for differentially expressed probesets. The theoretical (raw) p-values were then adjusted for multiple testing by controlling the false discovery rate (FDR). A cut-off of 0.05 was used on the FDR adjusted p-values to declare a probeset to be significant. For human studies, data are presented as mean ± SD unless otherwise stated. Cytokine levels are compared between groups using ANOVA with post hoc Fishers test. Patient demographics were compared using one-way ANOVA with Bonferroni post-hoc correction for continuous variables (age), and Pearson’s Chi-square for comparison of categorical variables for other demographic data. A p-value of 0.05 or less is considered significant.

Results
Myocardial Production and Release of SDF-1a are Similar in Murine and Human Myocardial Infarction Respectively
In the adult mammalian heart, mRNA encoding for SDF-1a and its cognate receptor CXCR4 are detectable at baseline. Following myocardial infarction, the constitutive expression of SDF-1a mRNA is reduced by approximately 25% at day 3, and this persists out to day 28 in all regions of the heart (Figure 1A). The

Figure 1 SDF-1a expression in the murine heart. There is reduced expression of mRNA for SDF-1a (A) in all regions of the murine heart following myocardial infarction. This occurs early, and remains suppressed for 28 days. There is no change in mRNA for its receptor CXCR4 (B). (C) Myocardial protein levels of SDF-1a are also reduced following MI. IZ = infarct zone; BZ = border zone of the infarct; RZ = remote zone. n = 3 for each region at each time-point.
expression of CXCR4, the receptor for SDF-1a, is unchanged in any region of the heart at either time-point following MI (Figure 1B). Similarly, the protein level of SDF-1a is reduced following MI (Figure 1C).

In humans, SDF-1a is constitutively released from the heart into the circulation at baseline, resulting in a positive gradient from the coronary artery to the coronary sinus (Table 1, Figure 2) and this release is suppressed after MI. Furthermore, SDF-1a release is also abolished in stable coronary artery disease and in unstable angina, suggesting that the presence of coronary artery disease, rather than the myocardial damage during MI, is responsible for the reduction in cardiac release of SDF-1a. The changes in cardiac production and release of SDF-1a in response to MI appear to be similar in the mouse and human.

**Myocardial Production and Release of MCP-1 Differ Between Murine and Human Myocardial Infarction**

At 3 days after MI, MCP1 mRNA increases 4-6 fold in all regions of the heart, and returns toward baseline by day 28 (Figure 3A). This time-dependent rise in the expression of the ligand is mirrored by its receptor CCR2 (Figure 3B). The protein level of MCP-1 is not increased in mice following MI (Figure 3C).

In humans, MCP-1 is constitutively released from the heart at baseline (Table 1). However, in direct contrast to the murine model, MCP-1 release from the heart is suppressed following myocardial infarction (Figure 4, Table 1). Furthermore, MCP-1 release is suppressed in stable CAD and unstable angina to similar degrees as following MI, suggesting that the presence of coronary artery disease, rather than the myocardial damage during MI, is responsible for the reduction in cardiac release of MCP-1. The changes in cardiac production and release of MCP-1 in response to MI appear to be the opposite in the mouse and human.

**Infarct Size Does Not Affect Human Myocardial Cytokine Release**

Transmyocardial gradient of MCP-1 and SDF-1a had no correlation with infarct size, as determined by peak troponin-I (TnI) level or peak creatinine kinase (CK) level. Pearson’s correlation r-value between TnI and MCP-1 was 0.02 (p = 0.95) and between TnI and SDF-1a was 0.31 (p = 0.30); between peak CK and MCP-1 was -0.06 (p = 0.88) and between CK and SDF-1a was 0.31 (p = 0.38).

**Influence of Timing and Patient Demographics After MI**

To ensure that the time post-MI that the samples were taken did not influence our results, we plotted the trans-myocardial gradients of SDF-1a and MCP-1 versus time from the MI. The trans-myocardial gradients of SDF-1a and MCP-1 were not related to the time measured after MI (Figure 5). Furthermore, the patients’ age, risk factors and medications were no different between groups. There was, however, a significantly higher percentage of males in the coronary artery disease groups compared to the normal controls (Table 2).

**Discussion**

This study has several important novel findings. Firstly, myocardial release of SDF-1a into the circulation is decreased in humans following MI and in all stages of coronary artery disease. Secondly, myocardial release of MCP-1 is also suppressed in patients post-MI and in the presence of coronary artery disease. Thirdly, and perhaps most importantly, the human release pattern of cytokines sometimes reflects the pattern seen in rodent
models, but in other cases it does not. This has significance for the progression of all translational research from murine studies.

Several authors have described different findings from ours; in particular, they have described increased SDF1a expression following MI [2,4,5]. However, we believe that this may be due to differences in strain of mouse used (CD1 mice in [2]) or species studied (rats in [4,5]). In contrast, we used C57Bl6 mice in our studies and found a decrease in RNA and protein expression.
However, discrepancies between strains and species lend weight to our conclusions that interspecies variations are significant, and that observational translational clinical trials are paramount before progressing to clinical trials of therapies based on rodent data.

SDF-1a has been shown to be chemoattractant for stem cells [2,4,23], pro-angiogenic [24] and anti-apoptotic for cardiac myocytes [25]. Whilst the stem cell chemotactic properties capture the imagination, the absence of release of SDF-1a from the human heart suggest that this may not be its primary mechanism of action following MI. Confounding the issue, and further emphasizing the difference between rodent models and man, is the presence of coronary artery disease in humans. The suppression of SDF-1a release from the heart in both stable and unstable coronary artery syndromes suggests that coronary artery disease itself reduces the release of SDF-1a. Perhaps the coronary artery plaques themselves sequester SDF-1a from the circulation. The mechanism of SDF-1a inducing cardiac repair remains incompletely understood, but our data demonstrates that in humans, SDF-1a release from the heart is reduced after MI. Some prior observational studies have shown increased peripheral blood levels of SDF-1a after MI [8,9] but our data would suggest that if elevated levels of SDF-1a are detected in peripheral blood, it originates from tissues other than the heart.

It is not known whether the reduction in cytokine release of SDF-1a and MCP-1 are beneficial or detrimental to the LV remodeling process. In the case of SDF-1a, we and others [1,7] have shown that there is reduced myocardial SDF-1a production, and there is experimental evidence that myocardial delivery of SDF-1a can repair damaged myocardium [25]. With our human data mimicking the murine data, it would be reasonable to speculate that SDF-1a delivery to damaged human myocardium would result in improved LV function. However, with respect to MCP-1, quite the opposite is true. Elevated levels of MCP-1 have been demonstrated in peripheral blood following MI [18-20] and higher levels correlate with poorer prognosis [21]. The animal model shows increased MCP-1 RNA in the hearts of rodents subjected to MI, and one might logically speculate that the elevated peripheral blood level of MCP-1 in humans after MI is produced by, and released from, the damaged heart tissue. A knockout animal
The model has shown that deletion of MCP-1 has a beneficial effect on post-infarction LV remodeling [26]. Extrapolating from all this, one might expect a strategy of MCP-1 antagonism after MI to be therapeutically effective. However, our data shows that there is no increased release of MCP-1 from the human heart following MI, in fact there is a decrease. Therefore, it would likely not be appropriate to pursue blockade of myocardial MCP-1 based on our current results. This underscores the importance of human observational clinical studies to ensure that the animal model is actually reflective of the human disease. Performing this step in the advancement from the bench to the bedside will prevent costly studies that, although reasonable based on animal study data, are unlikely to succeed based on the human data. This will avoid exposing patients to unnecessary risk and may save considerable amounts for ever-shrinking research budgets.

For all who study animal models of human disease, it is imperative to acknowledge that all models have limitations. While it is easy and relatively inexpensive to perform quantitative studies on murine cardiac mRNA, it is comparatively difficult and expensive to perform such studies on human cardiac tissue. Furthermore, there are ethical and logistic difficulties in procuring human heart samples. Thus, we frequently presume that the murine findings will apply to the human situation; our results suggest that this may not be the case. A limitation to our study is that we have not directly compared human mRNA to murine mRNA. This is because of the aforementioned difficulties in procuring human heart tissue. We also did not directly compare the transmyocardial release of these cytokines between species, because the coronary sinus in the mouse is simply too small to access. We therefore chose the most appropriate available samples to compare between species, but our results should be interpreted with these limitations in mind. Another limitation of our study is that there were more males in the 3 coronary artery disease groups than in the normal control group (which is reflective of coronary artery disease’s predilection for male subjects); therefore we cannot exclude gender differences as playing a small role in the differences between groups. However, we used all male mice in the murine study and showed similar response to MI with SDF-1a, but different response with MCP-1. This suggests that gender differences are less likely to have confounded our clinical results, but we cannot fully exclude the possibility of a gender effect in cytokine release profiles. This possibility warrants further study.

**Conclusions**

Release of SDF-1a from the heart into the circulation following MI is suppressed in humans, and this is similar to the murine model. Release of MCP-1 is also suppressed, but this is in direct contra-distinction to the murine model. Observational clinical studies like this are important to confirm whether the human disease state is accurately reflected by the animal model, and to guide future therapeutic strategies.

**List of Abbreviations Used**

- SDF-1a: Stromal-derived factor 1-alpha
- MCP-1: Monocyte chemotactic protein 1
- CCR2: C-C chemokine receptor 2
- CXCR4: CXC chemokine receptor 4
- MI: myocardial infarction
- LV: left ventricle
- KCl: potassium chloride
- mRNA: messenger ribonucleic acid

---

**Table 2 Patient demographics**

|                     | Normal n = 4 | Stable CAD n = 15 | Unstable Angina n = 6 | MI n = 21 |
|---------------------|--------------|-------------------|-----------------------|-----------|
| **Male** n (%)      |              |                   |                       |           |
|                     | 1 (25%)      | 10 (67%)          | 5 (83%)               | 19 (90%)  |
| **Age (years)**     | Mean +/- s.d |                   |                       |           |
|                     | 65 +/- 0.5   | 70 +/- 8.1        | 58 +/- 11             | 61 +/- 12 |
| **Cardiovascular Risk Factors** |               |                   |                       |           |
| Diabetes Mellitus n (%) |              |                   |                       |           |
|                     | 2 (50%)      | 6 (40%)           | 1 (17%)               | 11 (52%)  |
| Hypertension n (%)  |              |                   |                       |           |
|                     | 4 (100%)     | 12 (80%)          | 3 (50%)               | 13 (62%)  |
| Dyslipidemia n (%)  |              |                   |                       |           |
|                     | 2 (50%)      | 12 (80%)          | 4 (67%)               | 16 (76%)  |
| Family Hx n (%)     |              |                   |                       |           |
|                     | 0 (0%)       | 11 (73%)          | 4 (67%)               | 12 (57%)  |
| Smoking Hx n (%)    |              |                   |                       |           |
|                     | 1 (25%)      | 7 (47%)           | 4 (67%)               | 15 (71%)  |
| **Medications**     |              |                   |                       |           |
| Nitroglycerin n (%) |              |                   |                       |           |
|                     | 1 (25%)      | 5 (33%)           | 4 (67%)               | 7 (33%)   |
| Statin n (%)        |              |                   |                       |           |
|                     | 1 (25%)      | 7 (47%)           | 3 (50%)               | 14 (67%)  |
| ACEI/ARB n (%)      |              |                   |                       |           |
|                     | 2 (50%)      | 8 (53%)           | 2 (33%)               | 12 (57%)  |
| Beta Blocker n (%)  |              |                   |                       |           |
|                     | 1 (25%)      | 6 (40%)           | 5 (83%)               | 13 (62%)  |
| Aspirin n (%)       |              |                   |                       |           |
|                     | 2 (50%)      | 9 (60%)           | 3 (50%)               | 16 (76%)  |

*p < 0.05. CAD = coronary artery disease; MI = myocardial infarction; Hx = history; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker.

---

Boyle et al. *Journal of Translational Medicine* 2011, 9:150
http://www.translational-medicine.com/content/9/1/150

Page 7 of 8
Acknowledgements and Funding
This study was funded by the Ellison Medical Foundation and National Institutes of Health HL90915 (AB). Dr Wilson is funded by NHMRC Neil Hamilton Fairley and University of Melbourne Bickart Fellowships. Dr Jenkins is funded by the National Heart Foundation of Australia.

Author details
1Department of Medicine, Division of Cardiology, University of California San Francisco, San Francisco USA. 2St Vincent's Hospital Department of Medicine, University of Melbourne, Melbourne Australia.

Authors' contributions
AB conceived the study, collected human samples, performed animal experiments, data interpretation and manuscript preparation. YY conceived of study, collected human samples, study design and data analysis. AW conceived of study, collected human samples, data analysis and manuscript preparation. AJ performed ELISAs, data analysis. CK performed ELISAs and data analysis. RW collected human samples, data analysis and manuscript preparation. DP collected patient data and samples, data analysis. CW performed ELISAs and data analysis. AJ performed ELISAs and data interpretation and manuscript preparation. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 12 April 2011 Accepted: 12 September 2011 Published: 12 September 2011

References
1.  Wei Y-j, Tang Y, Li J, Cui C-j, Zhang H, Zhang X-l, Zhang H, Hu S-s: Effect of cardiac rehabilitation on angiogenic cytokines in postinfarction murine myocardial infarction. Harmsen MC: Induced in Rat Model of Myocardial Infarction. 2009, 24:122-128.
2.  Arakelyan A, Petrkova J, Hermanova Z, Boyajyan A, Lukl J, Petrek M: Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Myocardial Infarction. 2004, 110:236-243.
3.  Li, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of Monocyte Chemotractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice. Molecular Cell 1998, 2:275-281.
4.  Wang Y, Johnsen HE, Mortensen S, Bindslev L, Sejersten Ripa R, Haack-Boyle et al. Journal of Translational Medicine 2011, 9:150.
